Publicaciones en las que colabora con Luis M. Real (12)

2008

  1. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

    Immunogenetics, Vol. 60, Núm. 8, pp. 439-447

  2. Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

    Cancer Immunology, Immunotherapy

2007

  1. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

    Cancer Immunology, Immunotherapy, Vol. 56, Núm. 5, pp. 709-717

2001

  1. Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient

    Cancer Immunology, Immunotherapy, Vol. 49, Núm. 11, pp. 621-628

2000

  1. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression

    Cancer Immunology Immunotherapy, Vol. 48, Núm. 12, pp. 684-690

1999

  1. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors

    International Journal of Cancer, Vol. 83, Núm. 1, pp. 91-97

  2. Differential effect on U937 cell differentiation by targeting transcriptional factors implicated in tissue- or stage-specific induced integrin expression

    Experimental Hematology, Vol. 27, Núm. 2, pp. 353-364

  3. Expression of HLA G in human tumors is not a frequent event

    International Journal of Cancer, Vol. 81, Núm. 4, pp. 512-518

  4. Looking for HLA-G expression in human tumours

    Journal of Reproductive Immunology, Vol. 43, Núm. 2, pp. 263-273

1998

  1. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele

    International Journal of Cancer, Vol. 75, Núm. 2, pp. 317-323

  2. Microsatellite instability in cervical intraepithelial neoplasia

    Journal of Experimental and Clinical Cancer Research, Vol. 17, Núm. 3, pp. 361-366

  3. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line

    Cancer Immunology Immunotherapy, Vol. 47, Núm. 2, pp. 113-120